The safety of platelet transfusions is critical, and the recent US Food and Drug Administration (FDA) mandate requires bacterial risk mitigation strategies such as large volume delayed sampling or pathogen reduction. Processing requirements associated with these bacterial risk mitigation strategies may further erode the platelet supply.
